The Placebo Effect in Rare Disease Clinical Trials: Measurement, Impact, and Statistical Approaches for Patient-as-Own-Control Designs.

For objective continuous endpoints such as biomarker levels and physiological measurements, the SMD was only −0.12 (95% CI: −0.27 to 0.03), which did not reach statistical significance.

also in 111,027 other papers